Skip to main content

Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc. is an American biopharmaceutical company that discovers, invents, develops, manufactures, and commercializes medicines for serious medical conditions. The company focuses its proprietary technology platforms on proprietary antibody discovery across therapeutic areas including ophthalmology, immunology, oncology, hematology, and rare diseases. Its commercial drug portfolio includes flagship therapeutics such as Eylea for age-related macular degeneration, Dupixent (developed with Sanofi) for eczema and asthma, Libtayo for cancer, and Praluent for hypercholesterolemia. Principal revenue drivers consist of net product sales of proprietary medicines, profit-sharing collaborations with Sanofi and Bayer, and royalty income from international distribution agreements. Regeneron serves broad global end markets encompassing ophthalmologists, allergists, oncologists, hospital systems, specialty pharmacies, and patients across the United States, Europe, and Asia-Pacific. The corporation occupies a leading market position in biotechnology as a pioneer in human genetics-guided drug discovery and targeted biopharmaceutical therapies. Headquartered in Tarrytown, New York, the company's common stock is listed on the Nasdaq Stock Market under the ticker symbol REGN and is a component of the S&P 500 index.

105 of the funds FundTelligence covers report a position in Regeneron Pharmaceuticals.

Legal name
Regeneron Pharmaceuticals Inc.
Sector
Health Care
Country
United States
Funds holding it
105

Funds holding Regeneron Pharmaceuticals

Showing the 8 largest of 105 funds holding it.

Loading...